NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 137)
Posted On: 10/03/2018 4:57:47 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Fast-tracks UST Platform Development
Pressure BioSciences (OTCQB: PBIO) (“PBI”) today unveiled its intention to further commit substantial financial and operational support to fast-track the development of its Ultra Shear Technology (“UST”) platform, effective immediately. The company plans to pursue commercialization of its technology platform into major new markets. “We have committed approximately 2,000 sq. ft. of recently acquired space to our Ultra Shear Technology platform development and nanoemulsions commercialization program. We view this as an extraordinary opportunity that offers a range of major new market segments for PBI. We have instructed our Engineering and R&D personnel to finalize the development of our first-generation UST instrument and to make the generation of proof-of-principle nanoemulsion data for multiple product areas their top priority. We have also reallocated significant time and resources from several staff members to the UST platform development program,” Pressure BioSciences President and CEO Richard T. Schumacher stated in the news release. “Finally, we are rapidly accelerating discussions with multiple U.S., Canadian, and other companies, academic organizations, and government agencies that have expressed a strong desire to collaborate with PBI and acquire access to our proprietary UST process. We are on course to establish collaborative development projects with multiple companies and research groups addressing different product and market opportunities. These programs should lead to revenue-generating products in the near future. We believe there are many industries that can benefit from UST-produced nanoemulsions and that this can be an area of rapid and sizeable growth for PBI moving forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) (“PBI”) today unveiled its intention to further commit substantial financial and operational support to fast-track the development of its Ultra Shear Technology (“UST”) platform, effective immediately. The company plans to pursue commercialization of its technology platform into major new markets. “We have committed approximately 2,000 sq. ft. of recently acquired space to our Ultra Shear Technology platform development and nanoemulsions commercialization program. We view this as an extraordinary opportunity that offers a range of major new market segments for PBI. We have instructed our Engineering and R&D personnel to finalize the development of our first-generation UST instrument and to make the generation of proof-of-principle nanoemulsion data for multiple product areas their top priority. We have also reallocated significant time and resources from several staff members to the UST platform development program,” Pressure BioSciences President and CEO Richard T. Schumacher stated in the news release. “Finally, we are rapidly accelerating discussions with multiple U.S., Canadian, and other companies, academic organizations, and government agencies that have expressed a strong desire to collaborate with PBI and acquire access to our proprietary UST process. We are on course to establish collaborative development projects with multiple companies and research groups addressing different product and market opportunities. These programs should lead to revenue-generating products in the near future. We believe there are many industries that can benefit from UST-produced nanoemulsions and that this can be an area of rapid and sizeable growth for PBI moving forward.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼